已收盘 02-06 16:00:00 美东时间
+1.800
+3.84%
The FDA's warnings to Eli Lilly, Novo Nordisk and Hims & Hers spotlight risks for ETFs tied to the weight-loss drug boom.
2025-09-18 23:51
Needham analyst initiates coverage on Hims & Hers Health, Inc. with a Buy rating and $24 price target. Anticipates positive impact from GLP-1 market entry and strong growth potential.
2024-08-23 02:26